Morgan Stanley
RVPH

Morgan Stanley’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Morgan Stanley’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-8,530
Closed -$6.22K – 8555
2026
Q1 		$6.22K Sell
8,530
-8,336
-49% -$37.9K ﹤0.01% 7086
2025
Q4 		$94.1K Buy
16,866
+16,660
+8,087% +$185K ﹤0.01% 6230
2025
Q3 		$1.52K Hold
206
– – ﹤0.01% 7351
2025
Q2 		$1.57K Hold
206
– – ﹤0.01% 7273
2025
Q1 		$3.93K Sell
206
-100
-33% -$3.14K ﹤0.01% 7043
2024
Q4 		$11.1K Hold
306
– – ﹤0.01% 6765
2024
Q3 		$8.81K Sell
306
-590
-66% -$13.1K ﹤0.01% 6758
2024
Q2 		$22.9K Buy
896
+615
+219% +$28K ﹤0.01% 6413
2024
Q1 		$21.2K Sell
281
-196
-41% -$15.5K ﹤0.01% 6467
2023
Q4 		$49.1K Buy
477
+452
+1,808% +$40.6K ﹤0.01% 6390
2023
Q3 		$2.44K Sell
25
-13
-34% -$1.21K ﹤0.01% 7087
2023
Q2 		$4.44K Buy
+38
New +$4.82K ﹤0.01% 7013
2023
Q1 		– Sell
-1
Closed -$51 – 7814
2022
Q4 		$51 Buy
+1
New +$76 ﹤0.01% 7732

Other funds holding RVPH

ECM
EMC Capital Management Houston, Texas $253M AUM
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
PUI
Purpose Unlimited Inc Toronto $2.62B AUM
MGI
Miller Global Investments Dallas, Texas $121M AUM
MWM
Mosley Wealth Management Anaheim, California $314M AUM

Morgan Stanley's RVPH Position: Q2 2026 in Review

Morgan Stanley sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q2 2026, closing a stake of 8,530 shares — an estimated $6.22K sold.

Morgan Stanley first reported a position in RVPH in Q4 2022 and held it in 13 quarters. The position peaked at $94.1K in Q4 2025. 5 funds tracked by Wall St. Rank hold RVPH as of Q2 2026.

  • Morgan Stanley reported no remaining REVIVA PHARMA HLDGS INC position as of Q2 2026 after selling out during the quarter.
  • Morgan Stanley sold 8,530 REVIVA PHARMA HLDGS INC shares in Q2 2026, an estimated $6.22K.
  • Morgan Stanley first reported a position in REVIVA PHARMA HLDGS INC in Q4 2022 and held it in 13 quarters.
  • Morgan Stanley's REVIVA PHARMA HLDGS INC position peaked at $94.1K in Q4 2025.
  • 5 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.